• Dr. Navdeep Sharma

In the treatment of central nervous system and cardiovascular illnesses, Ginkgo biloba extract (GBE) has been extensively employed. A total of 17 preclinical studies and 20 clinical trials examining the therapeutic efficacy of GBE against Alzheimer's disease (AD) were retrieved from electronic sources; however, no systematic review has been undertaken. Meta-analysis of the AD-related pathological characteristics or symptoms was carried out by extracting the data from the reports and conducting Morri’s water maze cognitive function evaluations on 45 animals treated with GBE in six studies. In multiple experiments involving rats and mice, GBE was shown to minimize escape latencies (I2 > 70%, p 0.005). There were eight clinical studies with a total of 2100 participants. GBE increased the SKT and ADAS-Cog scores in early-stage Alzheimer's patients following long-term administration of high dosages and long-term administration. The research has two evident limitations: a lack of sample size calculations and low procedure quality. Preclinical and clinical findings, however, point to the necessity for future large-scale clinical studies in order to explore the effects of long-term GEB treatment on early-stage Alzheimer's disease (AD).

Ginkgo biloba extract; Alzheimer’s disease; clinical trial; meta-analysis

"GINGKO BILOBA ROLE IN PATIENTS WITH ALZHEIMER’S", International Journal of Emerging Technologies and Innovative Research (www.jetir.org), ISSN:2349-5162, Vol.7, Issue 5, page no.1261-1266, May 2020, Available :http://www.jetir.org/papers/JETIR2005487.pdf

"GINGKO BILOBA ROLE IN PATIENTS WITH ALZHEIMER’S", International Journal of Emerging Technologies and Innovative Research (www.jetir.org | UGC and issn Approved), ISSN:2349-5162, Vol.7, Issue 5, page no. pp1261-1266, May 2020, Available at : http://www.jetir.org/papers/JETIR2005487.pdf